Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-30
DOI
10.1007/s10637-021-01130-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors
- (2021) João Lobo et al. Molecular Oncology
- Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways
- (2021) Cinzia Caggiano et al. Cancers
- Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
- (2021) Parasvi S. Patel et al. ONCOGENE
- Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours
- (2020) Zuzana Cierna et al. BMC CANCER
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
- (2020) Ugo De Giorgi et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients
- (2020) Constantine Alifrangis et al. EUROPEAN JOURNAL OF CANCER
- Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Véronique Diéras et al. LANCET ONCOLOGY
- Molecular mechanisms of resistance in testicular germ cell tumors – Clinical implications
- (2018) Katarina Kalavska et al. CURRENT CANCER DRUG TARGETS
- Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
- (2018) Heidi J. Gray et al. GYNECOLOGIC ONCOLOGY
- PARP expression in germ cell tumours
- (2013) Michal Mego et al. JOURNAL OF CLINICAL PATHOLOGY
- Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial
- (2012) Anja Lorch et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition
- (2012) Francesca Cavallo et al. PLoS One
- Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design
- (2011) Darren R. Feldman et al. CANCER
- Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
- (2010) Svetlana Usanova et al. Molecular Cancer
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now